Airflow reversibility and long-term outcomes in patients with COPD without comorbidities

Respiratory Medicine

Volumn 108, Issue 8, 2014, Pages 1180-1188

  Marín, José Ma ^a,e   Ciudad, Maria ^a   Moya, Virginia ^a   Carrizo, Santiago ^a,e   Bello, Salvador ^a   Piras, Barbara ^b   Celli, Bartolomé R ^c   Miravitlles, Marc ^d,e  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF SASSARI   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bronchodilator test; COPD; Hospitalization; Mortality; Reversibility

Indexed keywords

SALBUTAMOL; BRONCHODILATING AGENT;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG RESPONSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SMOKING; DIAGNOSTIC USE; DRUG EFFECTS; INHALATION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VITAL CAPACITY;

BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; VITAL CAPACITY;

EID: 84906313954     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.05.006     Document Type: Article

References (37)

1. M. Miravitlles, J.B. Soriano, and F. García-Río et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities Thorax 64 2009 863 868
2. M. Decramer, W. Janssens, and M. Miravitlles Chronic obstructive pulmonary disease Lancet 379 2012 1341 1351
3. J.J. Soler-Cataluña, M.A. Martínez-García, P. Román-Sanchez, E. Salcedo, M. Navarro, and R. Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
4. Z. Matkovic, A. Huerta, and N. Soler et al. Predictors of adverse outcome in patients hospitalised for exacerbation of COPD Respiration 84 2012 17 26
5. J. García-Aymerich, I. Serra Pons, D.M. Mannino, A.K. Maas, D.P. Miller, and K.J. Davis Lung function impairment, COPD hospitalizations and subsequent mortality Thorax 66 2011 585 590
6. C. García-Polo, B. Alcázar-Navarrete, and L.A. Ruiz-Iturriaga et al. Factors associated with high resource utilisation among COPD patients Respir Med 106 2012 1734 1742
7. K. Nishimura, T. Izumi, M. Tsukino, and T. Oga Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD Chest 121 2002 1434 1440
8. C. Casanova, C. Cote, and J.P. De Torres et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 171 2005 591 597
9. J.M. Marin, I. Alfageme, and P. Almagro et al. Multicomponent indices to predict survival in COPD: the collaborative cohorts to assess multicomponent indices of COPD in Spain-COCOMICS study Eur Respir J 42 2013 323 332
10. B.R. Celli, C.G. Cote, and J.M. Marín et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012
11. J.B. Soriano, and D.M. Mannino Reversing concepts on COPD irreversibility Eur Respir J 31 2008 695 696
12. P. Albert, A. Agustí, and L. Edwards et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease Thorax 67 2012 701 708
13. P.M.A. Calverley, P.S. Burge, S. Spencer, J.A. Anderson, and P.W. Jones Bronchodilator reversibility testing in chronic obstructive pulmonary disease Thorax 58 2003 659 664
14. M. Miravitlles Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity Arch Bronconeumol 47 2011 271 272
15. M. Charlson, T. Szatrowski, J. Peterson, and J. Gold Validation of a combined comorbidity index J Clin Epidemiol 47 1994 1245 1251
16. B.G. Ferris Epidemiology standardization project Am Rev Respir Dis 118 Suppl. 1978 1 120
17. D. Mahler, and C. Wells Evaluation of clinical methods for rating dyspnea Chest 93 1988 580 586
18. American Thoracic Society Statement Lung function testing; selection of reference values and interpretative strategies Am Rev Respir Dis 144 1991 1202 1218
19. P.H. Quanjer, G.J. Tammeling, J.E. Cotes, O.F. Pedersen, R. Peslin, and J.C. Yernault Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official Statement of the European Respiratory Society Eur Respir J 16 Suppl. 1993 5 40
20. W.C. Tan, W.M. Vollmer, and B. Lamprecht et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease Study Thorax 67 2012 718 726
21. N.R. Anthonisen, P.G. Lindgren, D.P. Tashkin, R.E. Kanner, P.D. Scanlon, and J.E. Connett Bronchodilator response in the lung health study over 11 yrs Eur Respir J 26 2005 45 51
22. E.F. Hansen, K. Phanareth, L.C. Laursen, A. Kok-Jensen, and A. Dirksen Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease Am J Respir Crit Care Med 159 1999 1267 1271
23. 1 in evaluation of COPD severity COPD 9 2012 1 5
24. D.M. Mannino, E. Díaz-Guzman, and S. Buist Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study Respir Res 12 2011 136
25. N.A. Hanania, A. Sharafkhaneh, and B. Celli et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial Respir Res 16 2011 6
26. N.A. Hanania, B.R. Celli, J.F. Donohue, and U.J. Martin Bronchodilator reversibility in COPD Chest 140 2011 1055 1063
27. D.A. Mahler, J.F. Donohue, and R.A. Barbee et al. Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957 965
28. A. Papi, M. Romagnoli, and S. Baraldo et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease Am J Respir Crit Care Med 162 2000 1773 1777
29. J.H. Lee, Y.K. Lee, and E.K. Kim et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype Respir Med 104 2010 542 549
30. P. Weiner, M. Weiner, Y. Azgad, and D. Zamir Inhaled budesonide therapy for patients with stable COPD Chest 108 1995 1568 1571
31. E.R. Bleecker, A. Emmett, G. Crater, K. Knobil, and C. Kalberg Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility Pulm Pharmacol Ther 21 2008 682 688
32. R. Siva, R.H. Green, and C.E. Brightling et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Eur Respir J 29 2007 906 913
33. R. DiSantostefano, H. Li, D. Rubin, and D. Stempel Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis BMJ Open 3 2013 e001838 10.1136/bmjopen-2012-001838
34. M. Miravitlles, J.J. Soler-Cataluña, M. Calle, and J. Soriano Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice Eur Respir J 41 2013 1252 1256
35. M. Miravitlles, J.J. Soler-Cataluña, and M. Calle et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD Arch Bronconeumol 48 2012 247 257
36. M.K. Han, R. Wise, and J. Mumford et al. Prevalence and clinical correlates of bronchoreversibility in severe emphysema Eur Respir J 35 2010 1048 1056
37. I. Cerveri, R. Pellegrino, and R. Dore et al. Mechanisms for isolated volume response to a broncodilator in patients with COPD J Appl Physiol 88 2000 1989 1995